RonanRx entered YC promising personalized GLP-1s; service currently stops at Texas
Lloyd Armbrust and Emily Colman are pairing physician-set dosing with a separate compounding pharmacy while marketing a broader national buildout.
By Ryan Merket · Published
Primary source: Y Combinator
Why it matters
RonanRx is testing whether AI-guided, patient-specific prescribing can support a durable compounded GLP-1 business as regulators restrict standardized copies of branded drugs.
On August 4th, Lloyd Armbrust and Emily Colman launched RonanRx, an AI-assisted GLP-1 care platform in Y Combinator's Summer 2026 batch that proposes individualized dosing plans for physicians and coordinates fulfillment through a compounding pharmacy.…